Latest news

1 July 2022 09:00

Attgeno AB announces fully subscribed share issue to complete clinical phase II study in acute pulmonary hypertension

Attgeno AB announces that a successful share issue was completed at midsummer 2022 and resulted in SEK 20 million to a valuation of SEK 378 million after the issue. The issue consists of SEK 15 million in a rights issue to existing owners and a directed new issue of SEK 5 million to the Swedish life science focused venture fund Eir Ventures.

2 June 2022 11:00

Attgeno announces approval of initiation of Phase 2 clinical trial of Supernitro in patients with acute pulmonary hypertension

Attgeno AB today announced that it has received approval from the Swedish Medical Products Agency and the Swedish Ethical Review Authority to start a phase 2 clinical trial of its lead drug candidate Supernitro as a potentially lifesaving treatment for patients with acute pulmonary hypertension after cardiac surgery.

30 May 2022 06:00

Attgeno reports on the completed Phase I study of the drug candidate, Supernitro – paving the way for the next stage in the development of future treatments for acute pulmonary hypertension.

This now completed Phase I study confirms that Supernitro is a potent substance that works by releasing NO in the pulmonary blood vessels. The results from the study make the next step possible, in accordance with the goal that Attgeno has worked towards – to be able to study the effect of Supernitro in patients who have suffered APH following heart surgery.

17 March 2022 06:00

Attgeno announces the collaboration with a world-leading research center for pulmonary hypertension

Attgeno AB today announces a research collaboration with TransMIT GmbH, the technology transfer agency of Justus-Liebig-University of Giessen. Targeting to explore Supernitro (PDNO) as a new potential treatment for pulmonary hypertension by investigating specific drug mechanisms in the pathophysiology of the disease.

8 July 2021 05:00

Attgeno appoints Björn Westberg as CFO

Attgeno AB announces today that Björn Westberg has been appointed CFO and member of the management team at Attgeno. Björn most recently comes from a role as CFO at Enea AB (publ).

26 March 2021 06:00

Attgeno reports first healthy volunteers dosed with Supernitro in phase 1 trial

Attgeno AB today announced that the first 8 healthy volunteers have been successfully dosed in a phase 1 clinical study with the company’s lead drug candidate, Supernitro. The trial continues according to the clinical protocol and will include up to 48 healthy volunteers.